Sunitinib News and Research

RSS

Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.

Adolescent and young adult kidney cancer survivors at elevated risk for heart problems

New research out of VCU Massey Cancer Center indicates that many adolescent and young adult kidney cancer survivors are at a significantly elevated risk for heart issues.

5 Jul 2023

Mutations that lead to intracranial aneurysms discovered

Researchers at the RIKEN Center for Brain Science (CBS) in Japan have discovered a set of related mutations that lead to intracranial aneurysms-;weakened blood vessels in the brain that can burst at any time.

14 Jun 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Study contributes to better understanding of the changes in kinase activity in renal cell carcinoma

A new research paper was published in Oncotarget on August 4, 2022, entitled, "Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors."

17 Aug 2022

Chemical synthesis, properties, and molecular modeling studies of spiro-indole compounds

In a recent study under review at the Scientific Reports journal and currently posted to the Research Square* preprint server, researchers synthesized and evaluated the antitumoral (against several cancer cell lines) and antiviral [against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] properties of 3-spiro-indolin-2-ones.

15 Jun 2022

New study offers valuable information on ocular drug metabolism and pharmacokinetics

Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development.

29 Jan 2022

New combination immune therapy for cancer is effective and has fewer side effects, study finds

Google "chemotherapy side effects" and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. The list goes on and on.

13 Jan 2022

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.

10 Nov 2021

Targeted drug shows promising activity in kidney cancer patients with brain metastases

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

21 Oct 2021

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.

20 Sep 2021

First-in-kind kidney cancer drug developed at UTSW receives FDA approval

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

24 Aug 2021

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

13 Feb 2021

Potentially promising therapeutic combination for renal cell carcinoma uncovered

Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide.

20 Jan 2021

Trial shows new first-line treatment option for patients with metastatic kidney cancer

The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.

19 Sep 2020

Experts use genomic analysis tools to create personalized treatment for kidney cancer patients

Experts at City of Hope and the Translational Genomics Research Institute are using one of the world's most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.

22 Jul 2020

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

25 Nov 2019

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

13 Nov 2019

Epigenetic changes can lead to development of GISTs, other cancers

Most cases of gastrointestinal stromal tumor (GIST), a type of soft-tissue cancer (sarcoma), are caused by mutations in genes that can be effectively targeted with drugs that inhibit the activity of rogue cancer-promoting enzymes.

16 Oct 2019

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

18 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019